Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice

Fig. 6

Takinib reduces the cytokine and chemokine response in pro-inflammatory stimulated RA-FLS cells. RA-FLS cells were activated with TNF (30 ng/mL) and treated with 10 μM takinib or DMSO. A total of 40 cytokine and chemokine proteins were profiled. Takinib reduces the expression of G-CSF, ICAM, and CXCL1 (a, b, c, e) with modest change in MIP-1α (d) compared to vehicle control. Vehicle (DMSO) control (n = 4 ± SEM), 10 μM takinib (n = 4 ± SEM) (Students T test). RA-FLS cells were plated at 80% confluency and serum starved in 1% FBS media overnight following treatment with takinib at indicated concentrations (f) or takinib and TNF (30 ng/mL) (g) (n = 3 ± SEM) (two-way ANOVA, Dunnett’s post hoc). Relative cell viability was compared to DMSO control-treated cells following 24 and 48 h of treatment. Schematic of TAK1 signaling in pro-inflammatory stimulated cells and downstream effects (h). RFU = relative fluorescent units. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page